By Gerard Gallagher
Oral pre-exposure prophylaxis, or PrEP, for HIV prevention has a similar efficacy in women with “abnormal” vs. “normal” vaginal microbiota, according to recent findings.
By Tony Kirby
"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”.
By the School of Public Health
Testing the children of HIV-infected adults already receiving care may efficiently diagnose HIV-infected children before they exhibit symptoms, according to researchers from the University of Washington School of Public Health.
By referring HIV-infected parents to have their children tested, researchers revealed many untested older children and found that prevalence of HIV was high. This new active referral model significantly increased the rate of pediatric testing with limited additional costs to health systems.
Study involves researchers with UW International Clinical Research Center
By Bobbi Nodell
Researchers have found that breastfeeding mothers taking the antiretroviral drugs tenofovir and emtricitabine have a low risk of side effects. The study, published in PLOS, was conducted by colleagues at the UW International Clinical Research Center and partners in Kenya, Uganda and Johns Hopkins University.
By Bruce Jancin
DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.
“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.
The University of Washington is one of 56 DREAMS Innovation Challenge winners* announced on Monday by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Janssen Pharmaceutica NV (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson; and ViiV Healthcare.
New data analyses finds that a monthly vaginal ring containing an antiretroviral drug called dapivirine can cut women’s HIV risk by more than half and, in some, by 75 percent or more.
One of the researchers, Jared Baeten, a University of Washington professor of epidemiology, medicine and global health, presented the results Tuesday at the AIDS 2016 conference in Durban, South Africa.
By Lucy Tiven
On Tuesday, the Journal of the American Medical Association published a study on antiretroviral therapy (ART) and HIV transmission in mixed status couples — couples where one partner is HIV positive.
By Randy Dotinga
HealthDay Reporter
TUESDAY, July 12, 2016 (HealthDay News) -- HIV transmission is highly unlikely among straight couples who have sex without condoms when one partner carries the virus but takes medication, new research suggests.
For gay couples in the same scenario, the risk seems to be only slightly higher.
Rethinking how scientists share data -- especially the inconclusive results -- may be the key.
By Mark Wilson
The Collaboration for AIDS Vaccine Discovery (CAVD) consists of a group of labs across the world, all pooling their data with one goal in mind: to create an AIDS vaccine as fast as possible. But the theory of sharing vast amounts of data is easier than the practice.